Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ZNTL with free AI briefings, catalyst countdowns, and dilution alerts.

ZNTL · Zentalis Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$228.9M Cash on Hand
19.6mo Cash Runway
Follow ZNTL by email Get an email when ZNTL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ZNTL, unsubscribe in one click. Privacy

📣 What ZNTL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Azenosertib Ovarian Cancer Phase 3 · NCT07546500 Recruiting
Investigator's choice of chemotherapy Ovarian Cancer Phase 3 · NCT07546500 Recruiting
Gemcitabine Hydrochloride Advanced Pancreatic Adenocarcinoma Phase 2 · NCT06015659 Terminated
Asaretoclax Amyloidosis Phase 1/2 · NCT05199337 Completed
ZN-d5 ZN-c3 Acute Myeloid Leukemia (AML) Phase 1/2 · NCT05682170 Terminated
Pegylated Liposomal Doxorubicin Hydrochloride Solid Tumor Phase 1 · NCT04516447 Recruiting

Also used in these trials (approved or third-party drugs, not ZNTL's own candidates): Niraparib, Bevacizumab, Carboplatin, Cetuximab, Encorafenib, Paclitaxel, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ZNTL holds $228.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $35M/quarter from operations, an estimated runway of 19.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 62 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZNTL files for a raise →

👥 Who Owns ZNTL

Insiders 28.1% Other 5%+ holders 26.8% Institutions (165 holders) 45.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
WALTERS GROUP
10% owner
Insider 17,844,973 18.16% 2026-08-14
Walters William T 5%+ holder (13G) 17,844,973 18.16% 2026-08-14
Matrix Capital Management Company, LP
10% owner
Insider 6,459,973 6.57% 2025-12-15
Andrew J. Schwab 5%+ holder (13G) 4,838,571 4.92% 2025-12-18
Squadron Master Fund LP 5%+ holder (13G) 3,676,900 3.74% 2026-02-24
Andrea Paul
Chief Legal Officer · +124,714 options
Insider 1,070,784 1.09% 2025-02-03
Mark Lackner
Chief Scientific Officer · +124,714 options
Insider 512,856 0.52% 2025-02-03
Scott Dunseth Myers
Director
Insider 395,895 0.40% 2026-06-16
David Michael Johnson
Director
Insider 307,521 0.31% 2026-06-16
Jan Skvarka
Director
Insider 264,254 0.27% 2026-06-16
Luke Nathaniel Walker
Director
Insider 201,384 0.20% 2026-06-16
Enoch Kariuki
Director
Insider 194,465 0.20% 2026-06-16

Share count 98,265,863 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ZNTL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZNTL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.